This study focuses on patients with advanced hepatocellular carcinoma (liver cancer) that has spread to other parts of the body or cannot be removed by surgery. The research examines a combination treatment using three medications: nivolumab, relatlimab, and bevacizumab. These medications work by helping the body’s immune system fight cancer cells and by blocking the growth of blood vessels that feed tumors.
The study aims to find the best dose of these medications when used together and to determine how well they work compared to using only two of these medications. The research is divided into two parts. In the first part, different dose levels will be tested to ensure the combination is safe. In the second part, some patients will receive all three medications while others will receive only nivolumab and bevacizumab, along with a placebo.
During the study, participants will receive their assigned medications through intravenous infusions. The medications will be given at regular intervals, and patients will be monitored for how well the treatment works and any side effects that may occur. The study team will pay special attention to how the immune system responds to the treatment and will continue to monitor patients for several months after the last dose of medication.
France 
Germany 
Italy 
Poland 
Spain 
